JP2012525391A5 - - Google Patents

Download PDF

Info

Publication number
JP2012525391A5
JP2012525391A5 JP2012508570A JP2012508570A JP2012525391A5 JP 2012525391 A5 JP2012525391 A5 JP 2012525391A5 JP 2012508570 A JP2012508570 A JP 2012508570A JP 2012508570 A JP2012508570 A JP 2012508570A JP 2012525391 A5 JP2012525391 A5 JP 2012525391A5
Authority
JP
Japan
Prior art keywords
glycopeptide antibiotic
glycopeptide
binds
administration
bacterial infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012508570A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525391A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/032441 external-priority patent/WO2010129233A2/en
Publication of JP2012525391A publication Critical patent/JP2012525391A/ja
Publication of JP2012525391A5 publication Critical patent/JP2012525391A5/ja
Pending legal-status Critical Current

Links

JP2012508570A 2009-04-28 2010-04-26 オリタバンシンを用いた細菌感染の治療方法 Pending JP2012525391A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17345109P 2009-04-28 2009-04-28
US61/173,451 2009-04-28
PCT/US2010/032441 WO2010129233A2 (en) 2009-04-28 2010-04-26 Methods of treating bacterial infections using oritavancin

Publications (2)

Publication Number Publication Date
JP2012525391A JP2012525391A (ja) 2012-10-22
JP2012525391A5 true JP2012525391A5 (enExample) 2013-05-30

Family

ID=43050709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012508570A Pending JP2012525391A (ja) 2009-04-28 2010-04-26 オリタバンシンを用いた細菌感染の治療方法

Country Status (11)

Country Link
US (1) US9682061B2 (enExample)
EP (1) EP2424559B1 (enExample)
JP (1) JP2012525391A (enExample)
CN (1) CN102573882A (enExample)
AU (1) AU2010245097B2 (enExample)
BR (1) BRPI1014767A2 (enExample)
CA (1) CA2760159C (enExample)
ES (1) ES2981472T3 (enExample)
PL (1) PL2424559T3 (enExample)
PT (1) PT2424559T (enExample)
WO (1) WO2010129233A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027373T2 (hu) * 2008-08-30 2016-09-28 The Medicines Co Kezelési eljárások oritavancin egyszeri dózisainak alkalmazásával
US20130117413A1 (en) * 2010-07-20 2013-05-09 Sharp Kabushiki Kaisha Content distribution device, content playback device, content distribution system, method for controlling a content distribution device, control program, and recording medium
CN107206050A (zh) * 2014-07-17 2017-09-26 医药公司 高纯度奥利万星及其生产方法
US10534895B2 (en) 2015-01-20 2020-01-14 Icpd Technologies, Llc System and method for ranking options for medical treatments
KR20180111948A (ko) * 2016-02-18 2018-10-11 멜린타 테라퓨틱스, 인크. 오리타반신 제제
IL270686B (en) * 2017-05-22 2022-09-01 Insmed Inc Derivatives of glycopeptides and their uses
KR102189125B1 (ko) * 2018-11-30 2020-12-10 주식회사 리얼타임테크 로그 수집 시스템 및 그 수집 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
ES2316445T3 (es) 2000-05-02 2009-04-16 Theravance, Inc. Composicion que contiene una ciclodextrina y un antibiotico glicopeptidico.
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
US9089507B2 (en) * 2006-09-25 2015-07-28 The Medicines Company Use of oritavancin for prevention and treatment of anthrax
WO2008118784A1 (en) 2007-03-23 2008-10-02 Targanta Therapeutics Corp. Glycopeptide and lipoglycopeptide antibiotics with improved solubility
CA2699550C (en) * 2007-09-12 2020-08-18 Targanta Therapeutics Corp. Method of inhibiting clostridium difficile by administration of oritavancin
HUE027373T2 (hu) * 2008-08-30 2016-09-28 The Medicines Co Kezelési eljárások oritavancin egyszeri dózisainak alkalmazásával

Similar Documents

Publication Publication Date Title
JP2012525391A5 (enExample)
JP2016074740A5 (enExample)
JP2015529225A5 (enExample)
CN102065865B (zh) 多发性骨髓瘤治疗
JP2012067116A5 (enExample)
WO2009039972A3 (en) Use of muramyl dipeptide (mdp) as a therapeutic agent
RU2010140682A (ru) Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство
JP2016520573A5 (enExample)
WO2009033762A3 (en) Use of endothelin-3 as a therapeutic agent
WO2009043465A3 (en) Use of beta-endorphin as a therapeutic agent
WO2009033755A3 (en) Use of l-carnosine as a therapeutic agent
JP2016514132A5 (enExample)
JP2020521797A5 (enExample)
JP2013509389A5 (enExample)
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
JP2019517549A5 (enExample)
JP2018513188A5 (enExample)
JP2018507166A5 (enExample)
WO2009039957A3 (en) Use of angiotensin ii as a therapeutic agent in the treatment of eg s. pneumoniae infection
JP2015522033A5 (enExample)
JP2016537380A5 (enExample)
JP2005506345A5 (enExample)
JP2019511529A5 (enExample)
JP2022176345A (ja) 敗血症の処置のためのチモシンαの使用
IL265761B1 (en) Oral terlipressin compositions for use in treatment of ascites